Bayer's AskBio initiates Phase II GenePHIT trial in Congestive Heart Failure (CHF)
- Details
- Category: Bayer

TIVDAK® supplemental Biologics License Application accepted for Priority Review by FDA for patients with recurrent or metastatic cervical cancer
- Details
- Category: Pfizer

AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson's disease meets primary endpoint
- Details
- Category: Bayer

FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies
- Details
- Category: Roche

Pfizer declares first-quarter 2024 dividend
- Details
- Category: Pfizer

FDA grants Priority Review to Amgen's tarlatamab application for advanced small cell lung cancer
- Details
- Category: Amgen

Tarlatamab is a potential first-in-class, investigational delta-like ligand 3 (DLL3) targeting Bispecific T-cell Engager (BiTE®) therapy for the treatment of adult patients with advanced small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
AstraZeneca to acquire Icosavax
- Details
- Category: AstraZeneca

The proposed acquisition will build on AstraZeneca's expertise in respiratory syncytial virus (RSV), strengthening AstraZeneca's Vaccines & Immune Therapies late-stage pipeline with Icosavax's lead investigational vaccine candidate, IVX-A12. IVX-A12 is a potential first-in- class, Phase III-ready, combination protein VLP vaccine which targets both RSV and human metapneumovirus (hMPV),
More Pharma News ...
- Bayer and Salus Optima partner on AI-enabled healthy aging journey
- Pfizer announces topline Phase 2b results of oral GLP-1R agonist, danuglipron, in adults with obesity
- Bayer and Hurdle launch precision health strategic partnership
- Bayer invests 130 million EUR in new production facility for innovative parenteral products
- Pfizer and Astellas' XTANDI® approved by U.S. FDA in earlier prostate cancer treatment setting
- Roche's subcutaneous injection of Tecentriq recommended by the EU's CHMP for multiple cancer types
- Bayer and Recursion focus research collaboration on oncology